WILEX will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments and royalties.
UCB and WILEX will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to WILEX the relevant data to assist WILEX in oncology.
Ismail Kola, Executive Vice President and Chairman of New Medicine at UCB, said: “The pre-clinical work originated by UCB and continued by WILEX researchers to identify the immunology potential of one of the programs is of great interest to us. Leveraging UCB’s scientific expertise in immunology, we will now take the program forward and explore it further in immunology indications where there are severe unmet needs”.
Professor Olaf G. Wilhelm, Chairman of the Executive Management Board of WILEX AG, commented, “An identified lead antibody and generated data attracted UCB to purchase the rights to indications outside oncology at such an early stage which is not only a validation of our capabilities but also proof of our excellent partnership with UCB.”